Alzheimer's Association International Conference® | July 14-18, 2019 | Los Angeles, USA
July 14-18, Los Angeles, California
About AAIC
Learn about the world's largest forum for the dementia research community.
AAIC Scientific Program Committee
See the experts on the 2019 Committee.
Read about the individuals being honored for their
significant contributions to Alzheimer's research.
Attendee App Tutorial
Learn how to download and use this one-stop resource.
Learn how to get the most out of your AAIC experience.
The ISTAART Experience
View ISTAART events at AAIC or learn how to become a member.
To Do in Los Angeles
Traveling to Los Angeles
Get Our Attendee App
Download now to build your daily schedules, review abstracts, take notes and much more.
Abstract Submission Overview
AAIC Submissions
Alzheimer's Imaging Consortium Submissions
Technology and Dementia Submissions
Dementia Care Research and Practice Submissions
Developing Topics Submissions
Conference Policies
Abstracts Archive
Travel and Registration Fellowships
Q&A With an AAIC Plenary Speaker
Dementia Care Research and Practice Sessions
Emerging Concepts in Basic Science
Preconferences and Workshops
Professional Interest Area Events (PIAs)
The Basics of Biomarkers in Alzheimer's Disease
How to Interpret the Neuropathology Sign-Out Report
Basic Neuroimaging in Dementia
Contemporary Issues in Clinical Trials Methods
Health Disparities – Methodological Considerations
Commercializing a Novel Therapeutic Target for Alzheimer's Disease – Challenges and Opportunities
Alzheimer's Imaging Consortium
Technology and Dementia
Ancillary Meetings
Corporate Symposia - Non–CME
Daily Addenda
Learn about the benefits of exhibiting at AAIC.
Learn about opportunities to promote your brand at AAIC.
Learn about future sponsorship opportunities.
Virtual Press Room
Get general information for media, press releases and the latest news from AAIC.
See all 2019 AAIC press releases.
Read news featuring research presented at AAIC.
Get additional media resources, including b-roll footage and fact sheets.
Can Treating Sleep Problems Lower Dementia Risk?
« Back to All Press Releases
Download the complete news release
and related abstracts.
– Sleep disordered breathing may be a modifiable risk factor for Alzheimer's -
– Obstructive sleep apnea accelerates Alzheimer's disease biomarkers -
LONDON, July 18, 2017 — Several new research analyses reported at the Alzheimer's Association International Conference 2017 (AAIC 2017) in London found significant associations between sleep disordered breathing (SDB) and the accumulation of biomarkers for Alzheimer's disease. These findings highlight the idea that SDB is a modifiable factor that may help lower the risk of dementia and possibly slow the progression of dementia where it already exists.
Sleep disordered breathing is characterized by repeated episodes of hypopnea (under breathing) and apnea (not breathing) during sleep. The predominant form of apnea, Obstructive Sleep Apnea, occurs when an individual's upper airway closes partially or fully, but efforts to breath continue. OSA occurs in an estimated 3 in 10 men and 1 in 5 women.
Research reported at AAIC 2017 found:
SDB accelerated the accumulation of brain β-amyloid both in cognitively normal individuals and individuals with mild cognitive impairment (data from the Alzheimer's Disease Neuroimaging Initiative (ADNI)).
Obstructive sleep apnea (OSA) was associated with increased brain β-amyloid deposition, decreased cerebrospinal fluid (CSF) levels of β-amyloid and increased tau protein levels.
"The Centers for Disease Control and Prevention says more than one third of American adults do not get enough sleep on a regular basis. Clearly this is not good for brain health or overall health," said Dean M. Hartley, PhD, Alzheimer's Association Director of Science Initiatives. "Sleep disordered breathing is treatable in many cases. Through early diagnosis and effective treatment of these sleep disorders, there is the potential to improve cognition and possibly reduce dementia risk. But first we need to know more about the connections between these medical conditions."
Sleep-Disordered Breathing and Obstructive Sleep Apnea Are Associated With Amyloid Deposition
Three analyses reported by investigative teams at Wheaton College in Wheaton, Illinois, at AAIC 2017 examined sleep patterns among participants in ADNI to characterize potential effects of SDB and OSA on brain changes associated with mild cognitive impairment and Alzheimer's disease.
Amanda Shim and colleagues examined brain β-amyloid-42 accumulation in a cohort of 516 cognitively normal subjects and found that those with SDB had higher levels in CSF at baseline and more rapid accumulation over time. They found no interactive effect between OSA and the Alzheimer's risk gene APOE- e4. This suggests that OSA may be independently associated with brain amyloid burden.
Megan Hogan and colleagues performed similar analyses to assess the effects of OSA in 798 subjects with mild cognitive impairment (MCI). As with the cognitively normal cohort, both baseline β-amyloid-42 levels and the rate of accumulation were higher in subjects with OSA. While MCI does not always lead to dementia, a person with MCI is at an increased risk of developing Alzheimer's or another dementia. These results suggest that SDB may be an independent risk factor for Alzheimer's and raises the possibility that interventions aimed at treating SDB may also reduce Alzheimer's risk.
A combined analysis of the cognitively normal and mild cognitive impairment populations, plus a third group with Alzheimer's disease (n=325), evaluated the effects of OSA on levels of several Alzheimer's disease biomarkers in cerebrospinal fluid (CSF) and brain β-amyloid burden measured by positron emission tomography. Analyses showed:
Associations between OSA and CSF Aβ42 levels in the MCI and Alzheimer's groups.
Significant OSA associations were observed with [brain] Aβ42 levels in CN and MCI participants.
OSA subjects experienced faster increase in [brain] Aβ42 over time in the CN and MCI groups.
OSA participants experienced a faster decrease in CSF Aβ42 and increases in TAU and PTAU volumes over time in both the CN and MCI groups.
According to research team leader, Omonigho Bubu, MD, MPH, these results "highlight the importance of checking for and accurately diagnosing sleep disordered breathing, especially in people at risk for dementia, and more importantly in people diagnosed with MCI, so that it can be addressed and treated."
"If OSA accelerates deposition of beta amyloid in the brain, then it becomes a possible target for therapeutic intervention. More research is needed to confirm these findings," Bubu said.
The Alzheimer's Association International Conference (AAIC) is the world's largest gathering of researchers from around the world focused on Alzheimer's and other dementias. As a part of the Alzheimer's Association's research program, AAIC serves as a catalyst for generating new knowledge about dementia and fostering a vital, collegial research community.
AAIC 2017 home page: www.alz.org/aaic/
AAIC 2017 newsroom: www.alz.org/aaic/pressroom.asp
About the Alzheimer's Association®
The Alzheimer's Association is the leading voluntary health organization in Alzheimer's care, support and research. Our mission is to eliminate Alzheimer's disease through the advancement of research, provide and enhance care and support for all affected and reduce the risk of dementia through the promotion of brain health. Our vision is a world without Alzheimer's. Visit alz.org or call +1 800.272.3900.
Amanda Shim, et al. Sleep Disordered Breathing, APOE4 and β-Amyloid Deposition in Cognitive Normal Elderly. (Funder(s): Wheaton College Faculty Development Grant)
Megan Hogan, et al. Obstructive Sleep Is Associated with Longitudinal Increases in Amyloid Burden in Elderly Mild Cognitive Impairment Individuals. (Funder(s): Wheaton College Development Grant)
Omonigho Bubu, MD, MPH, et al. Effect of Obstructive Sleep Apnea (OSA) on Rate of Change of AD Biomarkers in Cognitive Normal, MCI and AD Elderly: Findings from the Alzheimer's Disease Neuroimaging Initiative (ADNI) Cohort. (Funder(s): Wheaton College Faculty Development Grant)
Alzheimer's Association International Conf. Press Office, +44 (0) 20-7069-6000, media@alz.org
Niles Frantz, Alzheimer's Association, +1 312-363-8782, nfrantz@alz.org
> 1200px
lg > 992px
md > 768px
sm < 767px